CureVac Right-sizes European Network For MRNA Product Pipeline

CureVac N.V. (CVAC), a German biopharmaceutical company, Tuesday said that it has decided to amend the long-term footprint of the external European manufacturing network for its messenger ribonucleic acid (mRNA) product pipeline.

The latest decision was in response to the decline in short-term peak demand for vaccines following the first wave of the pandemic vaccination efforts and corresponding changes in the demand of its first-generation Covid-19 vaccine candidate, CVnCoV.

The CVnCoV is currently under regulatory review with the European Medicines Agency (EMA).

Consequently, the company will terminate the existing contracts with WACKER for the manufacturing of the mRNA drug substance of CVnCoV and Celonic for the manufacturing and formulation of the mRNA drug substance of CvnCoV.

CureVac's existing agreements with Rentschler Biopharma and Novartis for mRNA production and formulation are intact and remain in place.

Streamlining of capacity does not limit the availability of clinical trial material for CV2CoV, the second-generation Covid-19 vaccine candidate jointly developed with GSK, expected to enter the clinic in the fourth quarter of 2021, the company said in a statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT